Testing a Drink to Lower Blood Sugar Levels in People With Type 2 Diabetes
Compares A1C Drink with a placebo drink over 3 months in type 2 diabetes.
Key facts
- Who runs it
- University of California, Riverside
- Where
- Riverside, United StatesSee the site
- Trial code
- Registry title
- A1Cantus vs. Placebo
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- 15 Jun 2026
- Expected to end
- 1 Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- A1C Drink
- Placebo drink
- Record updated
- 18 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 21 to 75 with type 2 diabetes and a high HbA1c (8 to 10), who take stable medicines and are recruited from UCR Health.
- Age
- 21 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with Ha1c of 8 or more and 10 or less.
- Earlier treatment
- Medications must have been stable for at least 6 months.
- Biomarker or test result
- Ha1c of 8 or more and 10 or less.
Main reasons for not taking part
- Major diabetes complications, such as CKD, diabetic retinopathy, ADVD risk > 5, or history of CVD/stroke
- Allergy to cinnamon
- Severe diseases, such as cancer, or a compromised immune system
- BMI of 40 or higher
- A family member or household member already in the study
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Adults 21 years of age or older and not older than 75 recruited from UCR Health
- Clinical diagnosis of type II DM with Ha1c >= 8 but less than or equal to 10
- Stable medications for at least 6 months
- Speak Spanish and/or English
- Sign an informed consent form
- No other members in their household are participating in the study
Who cannot take part
- Have major complications of diabetes, including CKD, diabetic retinopathy, ADVD risk > 5, or history of CVD/stroke
- Allergic to cinnamon
- Severe diseases, such as cancer
- Eating disorders
- Substance use disorder
- Patients <21 years of age, who do not have type II DM, whose Ha1c is less than 8 or > 10,
- Do not speak and understand either English or Spanish well
- Compromised immune system
- BMI of 40 or higher
- Already have a family member participating in the study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 75 years old?
Where in United States
- UCR HealthRiverside, United StatesContact: Elizabeth Jacobs, MD, MPPNot yet recruiting
About the trial
What the trial wants to find out
The investigators will conduct a randomized controlled 2-arm parallel trial of A1c Drink vs. Placebo over a 3-month period and compare changes in Ha1c from baseline to 3 months. Investigator and study personnel, as well as participants, will be blinded to drink assignments.
The 2 groups in the trial
- Placebo DrinkPlacebo, for comparison
The placebo drink will be formulated to closely match the active drink in taste, color and mouthfeel, while removing all active ingredients.
- A1C DrinkTreatment being tested
The A1C drink is currently on the market with natural active ingredients.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Double-Blind Randomized Controlled Trial of A1Cantus Drink vs. Placebo for Reduction of Ha1c
- Plain-language title
- Testing a Drink to Lower Blood Sugar Levels in People With Type 2 DiabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07585630, who can take part
- Record updated
- 18 May 2026